Problems › How Do We Get More Customers? › Healthcare Providers
More customers is an outcome. The decision is which route to them you can afford to repeat. This page works through it for healthcare providers specifically — including an unedited excerpt from a real analysis of a healthcare provider.
More customers is an outcome. The decision is which route to them you can afford to repeat. What makes this harder for healthcare providers is structural: downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Any credible answer therefore has to hold cost per episode and payer mix in the same view, which is exactly where most internal analysis stops because the two live in different systems.
Almost every business can name several ways to get customers and few can say which one pays back. That is the actual constraint: not a shortage of tactics, but no evidence about which tactic to do more of.
The productive framing is route economics. For each plausible route — outbound, referral, partners, search, events, channel — what does it cost to acquire one customer, how long until they pay that back, and can it be repeated without the cost rising as you scale it.
Most routes fail the third test. They work at small volume because they depend on the founder's network or attention, and quietly stop when either runs out.
These three together are the signature. One on its own usually points somewhere else.
✓ Growth depends on one person's relationships
✓ Cost per customer is unknown or known only in aggregate
✓ Every channel is being tried a little and none is being tested properly
The move that usually makes it worse. Running several channels at sub-scale simultaneously, which produces no conclusive result on any of them and costs more than testing one properly.
It is for you if you run or finance a healthcare provider and growth depends on one person's relationships. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Protect and grow the 34% operating-income ASC engine by replacing retiring surgeons and steering 212k attributed lives to the ASC within 24 months.
| Investment required | $3.0-4.0M total over 24 months ($1.8-2.2M surgeon succession + retention bonuses; $1.2-1.8M referral-optimization platform and analytics) |
| Expected return | Incremental $4.8-6.4M annual ASC contribution margin by Month 24; payback 14-18 months on $3.0-4.0M investment; lifts group operating margin from 4.2% to 5.8-6.4%. |
| Revenue, year 1 | $202-208M (ASC case volume +4-6%) |
| Revenue, year 2 | $212-220M (ASC case volume +6-8%; physician retention +2-3%) |
| Revenue, year 3 | $225-235M (ASC contribution ≥40% of operating income) |
| Exit criteria | Strategy abandoned if, by Month 12, fewer than two qualified orthopaedic surgeon candidates have signed LOIs OR if ASC case volume has not grown at least 2% YoY; in either case, board must decide within 30 days whether to pivot to hospital-system sale process at 8-10× EBITDA. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
The one where your buyer already is and where you can pay back the acquisition cost within a period you can finance. That is business-specific, and the general answer is worth very little.
One that works, then a second. Running four at a quarter of the necessary budget reliably produces four inconclusive results and the belief that nothing works.
Your sales cycle plus one payback period, with enough volume to distinguish the result from noise. Setting that number in advance is what stops the decision being made by whoever is most persuasive.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.